Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

>-- Raised $24.8 million in two successful public offerings

Strengthened Intellectual Property Portfolio:

-- Granted a U.S. patent for HPV fusions to treat patients with HPV-

related diseases

-- Granted a U.S. patent covering heat shock protein fusions to treat

anogenital warts

-- Won an important challenge to two U.S. patents; U.S. Patent and

Trademark Office reissued composition of matter and methods of use for

Company's CoVal(TM) fusions

-- Granted European patent covering CoVal(TM) fusion proteins to treat

influenza

Gregory M. McKee, President and Chief Executive Officer at Nventa commented on the year: "2007 was a year of significant events at Nventa. We are very pleased with the progress we made during the past year as we advanced new HspE7 (HspE7 + Poly-ICLC) into a Phase 1 clinical trial and completed the safety evaluation for three of the four cohorts in the trial. We anticipate completing the evaluation of the remaining cohort by the end of the second quarter of 2008, and are working diligently to design the Phase 2 clinical program, expected to begin shortly after this Phase 1 trial, to test new HspE7 in a larger population of patients with cervical dysplasia." Mr. McKee continued, "With the strength of our Directors, the addition of two new senior managers and the creation of a distinguished board of international experts, we look forward to building additional value for our shareholders through the continued advancement of new HspE7 for human papillomavirus (HPV)-related diseases."

Total Year 2007 and Fourth Quarter Financial Results:

All amounts, unless specified otherwise, are in Canadian dollars.

Nventa reported a net loss of $12,413,000, or $0.06 per share, for the year ended December 31, 2007, compared to a net loss of $10,067,000, or $0.12 per share, for the same period in 2006. The increase in net loss in 2007 from 2006 is principally re
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... BOSTON, MA (PRWEB) October 30, 2014 ... communication and collaboration provider, offers Office 365 end ... software into a complete phone system by adding ... Office 365 (O365) includes Lync Online, a communication ... to Lync calls. With hosted voice, O365 becomes ...
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... Al Khaimah, UAE (PRWEB) October 30, 2014 ... appointment of Dr. James A. Manganello, Chairman of the Board, ... of The Bahamas. The appointment was made by the ... Bahamas on September 24th, 2014. , More than ... Therapy and Research Bill , Prime Minister Perry Christie said ...
(Date:10/30/2014)... N.J. , Oct. 30, 2014  Regado Biosciences, ... it will hold a conference call and live audio ... EST to discuss its third quarter 2014 financial results. ... conference call by dialing (888) 347-1165 for domestic callers ... will be webcast live under the investor relations section ...
Breaking Biology Technology:SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... NBIX ) today announced its financial results for the ... the fourth quarter of 2010, the Company reported net income of ... loss of $7.9 million, or $0.20 per basic share, for the ... the Company reported a net loss of $8.0 million, or $0.15 ...
... Technologies, Inc., a privately-held orthobiologics company, announced today that ... is scheduled to present at Canaccord Genuity,s Musculoskeletal Conference ... February 15, 2011 at 10:00 AM (PT).  The conference, ... Meeting, will feature presentations from over 60 public and ...
... Mass., Feb. 10, 2011 Qteros, Inc., ... Bioprocessing (CBP) platform for the lowest-cost production ... engagements across the United States and Europe for members ... Qteros, Senior Vice President, Commercial Development and Engineering, will ...
Cached Biology Technology:Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 2Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 3Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 4Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 5Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 6Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 7ISTO Technologies, Inc. to Present at Canaccord Genuity's Musculoskeletal Conference 2Qteros Management to Present at Notable Alternative Energy Conferences in February 2
(Date:10/29/2014)... At a ceremony held in New York City on ... King, the American Cancer Society Professor of Genome Sciences ... and 2008 Honorary Doctor of Philosophy of Tel Aviv ... in Medical Science. , In addition to her honorary ... Lecturer at the TAU School of Medicine, and for ...
(Date:10/29/2014)... Hebei, China — BGI Tech and Hebei Agricultural University ... Jujube genome. Jujube is the most economically important member ... particularly difficult to sequence due the high level of ... time that a genome in the Rhamnaceae (Buckthorn) family ... in Nature Communications . , Jujube ...
(Date:10/28/2014)... the tragic realities of cancer is that the ... and their effectiveness varies unpredictably from patient to ... to change this reality by rapidly assessing how ... individual,s cancer before chemotherapy begins. , A team ... Assistant Professor Melissa Skala has developed the technique, ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3
... A new computer model of the Gulf of Mexico ... how underwater currents may have primed marine microorganisms to degrade ... of water move over the ruptured well, picking up hydrocarbons. ... over the well, the bacteria have already been activated, are ...
... Species pairs that disappear through hybridization after ... the disturbance is removed, according to a new ... reemergence might happen. The findings, published in ... conservationists and ecosystem managers interested in preserving, or ...
... Foundation for Biodiversity, the Charter Provincial Council of Gipuzkoa and ... be studying the re-stocking of the three eel phases (elver, ... and July, respectively, in three streams of the Oria basin. ... be able to manage the species and thus contribute to ...
Cached Biology News:Gulf currents primed bacteria to degrade oil spill 2Species reemergence after collapse: Possible but different 2A study will enable the survival and growth of the 3 development phases of the European eel 2
... The ProteoExtract™ Protein Precipitation Kit ... up of proteins from aqueous samples. ... by the presence of non-protein impurities ... in the protein sample that interfere ...
... activated carrier proteins to simplify the ... Activated Carrier Proteins are commonly used ... a heterobifunctional cross-linker (Sulfo-SMCC). This activation ... protein. Thus allowing the maleimide-activated ...
... This kit allows for rapid, convenient, ... The simple bind/wash/elute process utilizes a spin ... uses beads for concentration of proteins which ... beads are strong ion exchangers, offering high ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Biology Products: